Intuitive Surgical consensus holds steady, shares trade below recent high

By Anna Wagner, Analysts & Consensus desk. Reviewed prior to publication on 2026-06-25, 15:03.

Intuitive Surgical, Inc. (US46120E6023) remains widely covered by Wall Street brokers. The robotic surgery specialist continues to attract a predominantly positive analyst stance, while its shares trade on Nasdaq as a large-cap component of many U.S. healthcare portfolios.

What recent broker notes show

Analyst data compiled by MarketScreener indicates that more than two thirds of brokers currently rate Intuitive Surgical stock as Buy or equivalent, with the remainder largely at Hold and very few at Sell. MarketScreener's consensus overview for Intuitive Surgical shows an average 12-month price target modestly above the present market level, underlining a constructive but not euphoric view among research houses.

In recent weeks, several major brokers including Goldman Sachs and Morgan Stanley have reiterated positive views on robotic-assisted surgery penetration, emphasizing Intuitive Surgical's leading scale and installed base. These firms generally highlight recurring instrument and service revenue as a stabilizing factor for cash flows compared with pure capital-equipment peers. Reuters' analyst snapshot for Intuitive Surgical points to stable earnings estimates over the past month.

Earnings expectations this year

Consensus figures compiled by financial-data providers project solid double-digit revenue growth for Intuitive Surgical in the current fiscal year, driven by procedural volume increases and expansion of its installed base. For 2026, brokerage models typically assume continued expansion in the low double-digit range, supported by broader adoption of robotic-assisted laparoscopic procedures in general surgery and urology. Finanzen.net's analyst page for Intuitive Surgical shows broadly aligned earnings-per-share expectations among the main covering banks.

The company last reported quarterly earnings in April, delivering year-on-year revenue growth above 10 percent and growth in procedures performed with its systems, according to its investor materials. Operating margin trends remain an area of focus for analysts, who monitor the impact of R&D investment, manufacturing scale and pricing dynamics. Many models assume gradual margin improvement as volume increases, though they also factor in ongoing investment to support next-generation platforms.

How Intuitive Surgical makes money

Intuitive Surgical generates revenue primarily from selling and servicing robotic-assisted surgical systems, most prominently its da Vinci platform used in minimally invasive procedures across multiple specialties. The business model blends capital sales for systems with recurring revenue from instruments, accessories and service contracts, which together create a high-visibility stream tied to procedure volumes.

Where the stock trades today

Intuitive Surgical shares trade on Nasdaq under the ticker ISRG; the most recent available quote places the stock in the mid-300 USD range, with trading in U.S. dollars and the company categorized in the U.S. healthcare equipment and supplies sector.

This article was produced with AI assistance and editorially reviewed. Price and company figures without guarantee; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Stock-market transactions carry risks up to and including total loss.